FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229006470> ?p ?o ?g. }

• W4229006470 endingPage "8" @default.
• W4229006470 startingPage "8" @default.
• W4229006470 abstract "Chemotherapy-induced neuropathic pain (CINP) is a debilitating and difficult-to-treat side effect of chemotherapeutic drugs (e.g., oxaliplatin). CINP is marked with oxidative stress and neuronal hypersensitivities. The peroxisome proliferator-activated receptor gamma (PPARϒ) is a transcription factor that regulates genes involved in oxidative stress and inflammation. We hypothesize that PPARϒ agonists are protective against CIPN by reducing oxidative stress and inhibiting neuronal hypersensitivities. To test our hypothesis, we used a novel BBB (blood-brain barrier) penetrable PPARϒ agonist ELB00824 we characterized previously and a low BBB permeable PPARϒ agonist pioglitazone. CIPN was introduced in BALB/c mice (8-12 week old female) with two established treatment schedules of oxaliplatin injection (a short-lasting model with daily intraperitoneal (IP, 3 mg/kg) injection for 5 consecutive days and a long-lasting model with intravenous (IV, 5 mg/kg) injection twice per week for 4 weeks). 3, 10, or 30 mg/kg ELB00824 or pioglitazone was IP injected 5 min before each oxaliplatin treatment, and 30% DMSO, 15% [email protected] in PBS buffer was used as a vehicle control. Cold allodynia, mechanical allodynia, motor coordination, sedation and addiction were measured with dry ice, von Frey filaments, beam-walking tests, and conditioned place preference, respectively. Oxidative stress was accessed by measuring spinal carbonyl groups, thiobarbituric acid reactive substance (TBARS), and nitrotyrosine levels. Neuronal hypersensitivities were measured using whole-cell current clamp recordings in isolated dorsal root ganglion neurons. In both models ELB00824, but not pioglitazone, reduced oxaliplatin-induced cold and mechanical allodynia and spinal oxidative stress. ELB0824 suppressed oxaliplatin-induced firing in IB4- neurons. ELB00824 did not cause motor discoordination or sedation/addiction or reduce the antineoplastic activity of oxaliplatin (measured with an MTS-based cell proliferation assay) in a human colon cancer cell line (HCT116) and a human oral cancer cell line (HSC-3). Our results demonstrated that ELB00824 prevents oxaliplatin-induced pain, likely via inhibiting neuronal hypersensitivities and oxidative stress. Grant support from NIH grants R01DE029493 (Y. Ye). Chemotherapy-induced neuropathic pain (CINP) is a debilitating and difficult-to-treat side effect of chemotherapeutic drugs (e.g., oxaliplatin). CINP is marked with oxidative stress and neuronal hypersensitivities. The peroxisome proliferator-activated receptor gamma (PPARϒ) is a transcription factor that regulates genes involved in oxidative stress and inflammation. We hypothesize that PPARϒ agonists are protective against CIPN by reducing oxidative stress and inhibiting neuronal hypersensitivities. To test our hypothesis, we used a novel BBB (blood-brain barrier) penetrable PPARϒ agonist ELB00824 we characterized previously and a low BBB permeable PPARϒ agonist pioglitazone. CIPN was introduced in BALB/c mice (8-12 week old female) with two established treatment schedules of oxaliplatin injection (a short-lasting model with daily intraperitoneal (IP, 3 mg/kg) injection for 5 consecutive days and a long-lasting model with intravenous (IV, 5 mg/kg) injection twice per week for 4 weeks). 3, 10, or 30 mg/kg ELB00824 or pioglitazone was IP injected 5 min before each oxaliplatin treatment, and 30% DMSO, 15% [email protected] in PBS buffer was used as a vehicle control. Cold allodynia, mechanical allodynia, motor coordination, sedation and addiction were measured with dry ice, von Frey filaments, beam-walking tests, and conditioned place preference, respectively. Oxidative stress was accessed by measuring spinal carbonyl groups, thiobarbituric acid reactive substance (TBARS), and nitrotyrosine levels. Neuronal hypersensitivities were measured using whole-cell current clamp recordings in isolated dorsal root ganglion neurons. In both models ELB00824, but not pioglitazone, reduced oxaliplatin-induced cold and mechanical allodynia and spinal oxidative stress. ELB0824 suppressed oxaliplatin-induced firing in IB4- neurons. ELB00824 did not cause motor discoordination or sedation/addiction or reduce the antineoplastic activity of oxaliplatin (measured with an MTS-based cell proliferation assay) in a human colon cancer cell line (HCT116) and a human oral cancer cell line (HSC-3). Our results demonstrated that ELB00824 prevents oxaliplatin-induced pain, likely via inhibiting neuronal hypersensitivities and oxidative stress. Grant support from NIH grants R01DE029493 (Y. Ye)." @default.
• W4229006470 created "2022-05-08" @default.
• W4229006470 creator A5001434696 @default.
• W4229006470 creator A5022613895 @default.
• W4229006470 creator A5032920452 @default.
• W4229006470 creator A5037245619 @default.
• W4229006470 creator A5044741701 @default.
• W4229006470 creator A5045617018 @default.
• W4229006470 creator A5071419471 @default.
• W4229006470 date "2022-05-01" @default.
• W4229006470 modified "2023-10-16" @default.
• W4229006470 title "A Novel PPAR Gamma Agonist ELB00824 Suppresses Oxaliplatin-induced Pain, Neuronal Hypersensitivity, and Oxidative Stress" @default.
• W4229006470 doi "https://doi.org/10.1016/j.jpain.2022.03.032" @default.
• W4229006470 hasPublicationYear "2022" @default.
• W4229006470 type Work @default.
• W4229006470 citedByCount "0" @default.
• W4229006470 crossrefType "journal-article" @default.
• W4229006470 hasAuthorship W4229006470A5001434696 @default.
• W4229006470 hasAuthorship W4229006470A5022613895 @default.
• W4229006470 hasAuthorship W4229006470A5032920452 @default.
• W4229006470 hasAuthorship W4229006470A5037245619 @default.
• W4229006470 hasAuthorship W4229006470A5044741701 @default.
• W4229006470 hasAuthorship W4229006470A5045617018 @default.
• W4229006470 hasAuthorship W4229006470A5071419471 @default.
• W4229006470 hasBestOaLocation W42290064701 @default.
• W4229006470 hasConcept C118552586 @default.
• W4229006470 hasConcept C121608353 @default.
• W4229006470 hasConcept C126322002 @default.
• W4229006470 hasConcept C134018914 @default.
• W4229006470 hasConcept C15490471 @default.
• W4229006470 hasConcept C170493617 @default.
• W4229006470 hasConcept C185592680 @default.
• W4229006470 hasConcept C2776151105 @default.
• W4229006470 hasConcept C2776281502 @default.
• W4229006470 hasConcept C2777107010 @default.
• W4229006470 hasConcept C2777180221 @default.
• W4229006470 hasConcept C2777883359 @default.
• W4229006470 hasConcept C2778384471 @default.
• W4229006470 hasConcept C2778938600 @default.
• W4229006470 hasConcept C2779245659 @default.
• W4229006470 hasConcept C2780775167 @default.
• W4229006470 hasConcept C2780962732 @default.
• W4229006470 hasConcept C42219234 @default.
• W4229006470 hasConcept C526805850 @default.
• W4229006470 hasConcept C555293320 @default.
• W4229006470 hasConcept C71924100 @default.
• W4229006470 hasConcept C98274493 @default.
• W4229006470 hasConceptScore W4229006470C118552586 @default.
• W4229006470 hasConceptScore W4229006470C121608353 @default.
• W4229006470 hasConceptScore W4229006470C126322002 @default.
• W4229006470 hasConceptScore W4229006470C134018914 @default.
• W4229006470 hasConceptScore W4229006470C15490471 @default.
• W4229006470 hasConceptScore W4229006470C170493617 @default.
• W4229006470 hasConceptScore W4229006470C185592680 @default.
• W4229006470 hasConceptScore W4229006470C2776151105 @default.
• W4229006470 hasConceptScore W4229006470C2776281502 @default.
• W4229006470 hasConceptScore W4229006470C2777107010 @default.
• W4229006470 hasConceptScore W4229006470C2777180221 @default.
• W4229006470 hasConceptScore W4229006470C2777883359 @default.
• W4229006470 hasConceptScore W4229006470C2778384471 @default.
• W4229006470 hasConceptScore W4229006470C2778938600 @default.
• W4229006470 hasConceptScore W4229006470C2779245659 @default.
• W4229006470 hasConceptScore W4229006470C2780775167 @default.
• W4229006470 hasConceptScore W4229006470C2780962732 @default.
• W4229006470 hasConceptScore W4229006470C42219234 @default.
• W4229006470 hasConceptScore W4229006470C526805850 @default.
• W4229006470 hasConceptScore W4229006470C555293320 @default.
• W4229006470 hasConceptScore W4229006470C71924100 @default.
• W4229006470 hasConceptScore W4229006470C98274493 @default.
• W4229006470 hasIssue "5" @default.
• W4229006470 hasLocation W42290064701 @default.
• W4229006470 hasOpenAccess W4229006470 @default.
• W4229006470 hasPrimaryLocation W42290064701 @default.
• W4229006470 hasRelatedWork W1974508905 @default.
• W4229006470 hasRelatedWork W2040002172 @default.
• W4229006470 hasRelatedWork W2065765759 @default.
• W4229006470 hasRelatedWork W2067469588 @default.
• W4229006470 hasRelatedWork W2117351537 @default.
• W4229006470 hasRelatedWork W2380552259 @default.
• W4229006470 hasRelatedWork W2395081757 @default.
• W4229006470 hasRelatedWork W2566839157 @default.
• W4229006470 hasRelatedWork W2767026395 @default.
• W4229006470 hasRelatedWork W3111281130 @default.
• W4229006470 hasVolume "23" @default.
• W4229006470 isParatext "false" @default.
• W4229006470 isRetracted "false" @default.
• W4229006470 workType "article" @default.